These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12570738)

  • 1. Genomic pathways to antifungal discovery.
    Monk BC; Cannon RD
    Curr Drug Targets Infect Disord; 2002 Dec; 2(4):309-29. PubMed ID: 12570738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of yeast in drug discovery.
    Ma D
    Prog Drug Res; 2001; 57():117-62. PubMed ID: 11728000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB; Geyer R; Hughes TR; Boone C
    Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fun(gi)omics: Advanced and Diverse Technologies to Explore Emerging Fungal Pathogens and Define Mechanisms of Antifungal Resistance.
    Ball B; Langille M; Geddes-McAlister J
    mBio; 2020 Oct; 11(5):. PubMed ID: 33024032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of human fungal pathogens to antifungal drugs.
    Sanglard D
    Curr Opin Microbiol; 2002 Aug; 5(4):379-85. PubMed ID: 12160856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in functional genomics approaches to antifungal drug target discovery.
    De Backer MD; Van Dijck P
    Trends Microbiol; 2003 Oct; 11(10):470-8. PubMed ID: 14557030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungals.
    Campoy S; Adrio JL
    Biochem Pharmacol; 2017 Jun; 133():86-96. PubMed ID: 27884742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics and the prospects for the discovery of new targets for antibacterial and antifungal agents.
    Isaacson RE
    Curr Pharm Des; 2002; 8(13):1091-8. PubMed ID: 12052221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and genetic approaches for the identification of antifungal drug targets.
    Agarwal AK; Xu T; Jacob MR; Feng Q; Li XC; Walker LA; Clark AM
    Infect Disord Drug Targets; 2008 Mar; 8(1):2-15. PubMed ID: 18473903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beauvericin Potentiates Azole Activity via Inhibition of Multidrug Efflux, Blocks Candida albicans Morphogenesis, and Is Effluxed via Yor1 and Circuitry Controlled by Zcf29.
    Shekhar-Guturja T; Tebung WA; Mount H; Liu N; Köhler JR; Whiteway M; Cowen LE
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7468-7480. PubMed ID: 27736764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomics strategies for antifungal drug discovery--from gene discovery to compound screening.
    Willins DA; Kessler M; Walker SS; Reyes GR; Cottarel G
    Curr Pharm Des; 2002; 8(13):1137-54. PubMed ID: 12052224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
    Keniya MV; Ruma YN; Tyndall JDA; Monk BC
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics, molecular targets and the discovery of antifungal drugs.
    Odds FC
    Rev Iberoam Micol; 2005 Dec; 22(4):229-37. PubMed ID: 16499416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Response to Drugs and Stress in the Pathogenic Yeast Candida glabrata.
    Pais P; Galocha M; Teixeira MC
    Prog Mol Subcell Biol; 2019; 58():155-193. PubMed ID: 30911893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress in the study of fungal virulence factors and identification of new targets of anti-fungal drug using proteomic and transcriptomic analysis].
    Toyotome T; Watanabe A; Kamei K
    Nihon Rinsho; 2008 Dec; 66(12):2255-60. PubMed ID: 19069088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungals discovery: an insight into new strategies to combat antifungal resistance.
    Fuentefria AM; Pippi B; Dalla Lana DF; Donato KK; de Andrade SF
    Lett Appl Microbiol; 2018 Jan; 66(1):2-13. PubMed ID: 29112282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative genomic and transcriptomic analyses unveil novel features of azole resistance and adaptation to the human host in Candida glabrata.
    Salazar SB; Wang C; Münsterkötter M; Okamoto M; Takahashi-Nakaguchi A; Chibana H; Lopes MM; Güldener U; Butler G; Mira NP
    FEMS Yeast Res; 2018 Feb; 18(1):. PubMed ID: 29087506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.